Volpara on track to break even as revenue climbs 34%

Volpara on track to break even as revenue climbs 34%
Volpara benefits from US decision. (Image: Getty)
Staff reporters
Volpara Health Technologies is on track to break even on an underlying earnings basis after notching up record revenue and scoring a win when the US Food and Drug Administration (FDA) required density notification in mammogram reports. The Wellington-based, ASX-listed company narrowed its net loss to $9.8 million in the 12 months ended March 31, from $16.4m a year earlier, as revenue climbed 34% to $35m. That record revenue figure beat Volpara’s initial guidance range of $33.5m to $34.5m. The company reported a loss before inter...